Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/37284
Title: Effect of bevacizumab and everolimus combination treatment on peritoneal sclerosis in an experimental rat model
Authors: Açıkgöz Mert, Gizem Sultan
Çeri, Mevlüt
Çalli Demirkan, Neşe
Şahin, Barbaros
Mert, Mehmet
Dursun, Belda
Keywords: bevacizumab
everolimus
MMP-2
peritoneal dialysis
peritoneal thickness, sclerosis
Publisher: Blackwell Publishing Ltd
Abstract: The aim of this study was to investigate whether bevacizumab and everolimus combination therapy is superior to bevacizumab treatment alone as a treatment for peritoneal sclerosis. Forty Wistar albino rats were divided into five equal groups. The control group received isotonic saline solution (2 mL/day) intraperitoneal (IP) daily for 3 weeks. The CG group received 2 mL 0.1% chlorhexidine gluconate (CG) and 15% ethanol dissolved in saline IP daily for 3 weeks. Peritoneal tissue samples were taken at the end of 3 weeks. The resting group received CG (weeks 0-3), plus isotonic saline solution (2 mL/day) IP daily and tap water (2 mL/day) via a feeding tube daily (weeks 3-6).The bevacizumab group received CG (weeks 1-3) plus bevacizumab at 2.5 mg/kg/day (2 mL) IP daily and tap water (2 mL/day) via a feeding tube daily (weeks 3-6). The bevacizumab+everolimus group received CG (weeks 1-3) plus bevacizumab at 2.5 mg/kg/day (2 mL) IP daily and everolimus at 0.3 mg/kg/day (2 mL) via a feeding tube daily (weeks 3-6). Peritoneal tissue samples were taken from these three groups at the end of 6 weeks and were examined after staining with hematoxylin-eosin and Masson's trichrome. Inflammation, vasculopathy, fibrosis, and peritoneal thickness were evaluated under light microscopy. The samples were also stained with anti-TGF-ß and anti-MMP-2. Inflammation and vasculopathy scores were significantly decreased in the VEGF-i group compared to the CG group. The addition of everolimus to VEGF-i showed significantly lower inflammation, vasculopathy, fibrosis scores, and an evident decrease in peritoneal thickening (respectively, 2.29 ± 0.76 vs 0.57 ± 0.53, P =.003; 2.71 ± 0.76 vs 1.43 ± 0.53, P =.008; 2.57 ± 0.79 vs 1.57 ± 0.79, P =.04; 247.5 ± 136.1 vs 84.5 ± 48.6, P =.048). MMP-2 levels were lower in the combination group compared to the resting group (2.63 ± 0.74 vs 1.86 ± 0.38, P =.019). The study results demonstrated that bevacizumab and everolimus combination therapy was more effective than bevacizumab therapy alone. © 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy
URI: https://hdl.handle.net/11499/37284
https://doi.org/10.1111/1744-9987.13565
ISSN: 1744-9979
Appears in Collections:Acıpayam Meslek Yüksekokulu Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Dec 7, 2024

WEB OF SCIENCETM
Citations

1
checked on Dec 12, 2024

Page view(s)

58
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.